Crescent Capital BDC (CCAP) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on May 16, 2025, with full participation rights for stockholders.
Stockholders will vote on electing two Class I Directors, ratifying Ernst & Young LLP as auditor for 2025, and any other business.
The record date for voting is March 19, 2025, with 37,061,547 shares of common stock outstanding.
Proxy materials, including the annual report, are available online, and multiple voting methods are provided.
Voting matters and shareholder proposals
Proposals include electing two Class I Directors (Kathleen S. Briscoe and George G. Strong, Jr.) for terms expiring in 2028.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Board unanimously recommends voting FOR both proposals.
Shareholder proposals for the 2026 meeting must be submitted by November 26, 2025.
Board of directors and corporate governance
Board consists of six directors, five of whom are independent; no lead independent director is designated.
Board committees include Audit, Nominating, and Compensation, each chaired by an independent director.
Annual self-assessment of board and committee structure is conducted.
Directors are selected based on character, expertise, and ability to represent stockholder interests.
Latest events from Crescent Capital BDC
- Q4 net investment income covered the dividend, with NAV at $19.10 and a defensively positioned portfolio.CCAP
Q4 202526 Feb 2026 - Q2 2024 NII reached $0.59/share, NAV $20.30, with strong liquidity and stable credit.CCAP
Q2 20241 Feb 2026 - Q3 net investment income rose to $0.64 per share, with strong liquidity and low non-accruals.CCAP
Q3 202414 Jan 2026 - Q4 2024 featured lower NII, stable NAV, robust liquidity, and special dividends for 2025.CCAP
Q4 202424 Dec 2025 - Board urges ratification of Ernst & Young LLP as auditor, with 2024 fees totaling $841,150.CCAP
Proxy Filing2 Dec 2025 - Director elections and auditor ratification headline the 2025 annual meeting agenda.CCAP
Proxy Filing2 Dec 2025 - Net investment income and NAV per share fell, but dividends and portfolio quality remain strong.CCAP
Q1 202526 Nov 2025 - Q2 2025 delivered strong income, stable NAV, and a $20M share repurchase program.CCAP
Q2 202523 Nov 2025 - Net investment income steady at $0.46 per share; NAV and net income per share declined.CCAP
Q3 202517 Nov 2025